Benefits
Skin sensitivity to UV light (single small trial, maker-reported)
In a 4-week study, 13 men with UV-sensitive skin took 160 mg a day. A short summary paper by Indena-linked authors reports that the UV dose needed to redden the skin rose 14.5 percent and tolerated exposure time 14.1 percent versus placebo; Indena's brochure gives 16.45 percent versus baseline. Group sizes and full data are not available, and it is no substitute for sunscreen.
Fasting blood glucose: one small 12-week trial
In a randomized, double-blind trial in 15 adults on blood pressure medication with borderline fasting glucose, 8 took 100 mg a day of Indena's olive fruit extract (cited by Indena as Opextan) and 7 took olive oil placebo for 12 weeks. Fasting glucose fell from 116.6 to 105.8 mg/dL with the extract (p = 0.042) but not with placebo; no between-group test was reported, the extract group started higher, and HbA1c did not change.
Urinary oxidation marker (maker-reported, no control group described)
In 19 healthy volunteers taking 400 mg a day for 4 weeks, urinary 8-isoprostane, a marker of lipid peroxidation, fell from baseline: by 36.4 percent in a summary paper by Indena-linked authors and by 47 percent in Indena's brochure, whose chart shows several people rose. No control group is described. In the 12-week trial at 100 mg a day, the DNA oxidation marker 8-OHdG did not change.
Verbascoside antioxidant activity (in vitro only)
Verbascoside is the polyphenol Opextan is standardized to. In test-tube assays it was more active than caffeic acid or hydroxytyrosol in some antioxidant tests, while a phenol mixture and whole olive extracts protected DNA from oxidation better than single compounds (PMID 19099401). Indena's own assay rates it about 5 times more active than oleuropein. Activity in a test tube does not show an antioxidant effect in the body.
UV damage in skin cells (in vitro only)
In vitro, verbascoside made in cultured lilac cells protected human keratinocytes from UV-C induced necrosis, though not from apoptosis (PMID 18404597), and an oleuropein, hydroxytyrosol and verbascoside mix reduced UVB-induced inflammatory and collagen-breakdown markers in skin cells (PMID 41266576). Neither study used Opextan or olive fruit extract, and neither tested oral intake.
Topical face studies (not evidence for capsules)
Indena reports two studies of Opextan applied to the face: a 0.5 percent formula on half the face of 6 volunteers lowered sebum lipid peroxidation after sun exposure by about 27 percent versus the placebo side, and a 2.5 percent formula used twice daily for 3 months by 23 men improved skin roughness on replicas versus a blank formula. Neither is in a PubMed-indexed journal, and creams say nothing about capsules.
Blood pressure and cholesterol: no change in the one trial
In the 12-week trial at 100 mg a day, blood pressure, total and HDL cholesterol, triglycerides and liver enzymes did not change significantly, though every participant was already taking blood pressure medication. No study has tested Opextan for heart health, and a concentrated extract is not the same as olive oil eaten as part of a Mediterranean diet.
Mechanism of action
Verbascoside free radical scavenging
Verbascoside (also called acteoside) is a phenylethanoid glycoside that scavenges hydroxyl, superoxide and nitric oxide radicals, chelates iron and copper ions and inhibits lipid peroxidation in laboratory work (PMID 18404597). Whether this happens in human tissue after swallowing a capsule has not been shown.
Polyphenol mixture (laboratory hypothesis)
Opextan contains verbascoside, hydroxytyrosol, tyrosol and isoacteoside together. In test-tube assays some olive phenol mixtures and whole extracts protected DNA from oxidation better than single compounds (PMID 19099401), and a three-compound mix reduced UVB damage markers in skin cells (PMID 41266576). No study has compared the blend with single compounds in people.
Skin barrier (animal data only)
The proposed idea is that olive polyphenols limit oxidative damage to skin lipids. Indena reports that verbascoside given by mouth reduced UVB-induced water loss through the skin and wrinkle formation in hairless mice, but no human study of oral Opextan has measured skin barrier function.
UV-induced oxidative stress
UV light generates reactive oxygen species that damage skin cells, and in a dish verbascoside and related olive polyphenols reduce that damage (PMID 18404597, PMID 41266576). The only human oral data are the maker-reported 13-man UV sensitivity study, which has not been independently published. Do not rely on Opextan for sun protection.
Alpha-glucosidase inhibition (proposed glucose mechanism)
Indena reports that the extract inhibits the carbohydrate-digesting enzyme alpha-glucosidase in a test tube, and the trial authors proposed this, plus better insulin secretion, to explain the lower fasting glucose. In the trial itself, insulin resistance (HOMA-IR) did not change and the rise in the insulin secretion index (HOMA-beta) was not significant.
Clinical trials
Oral study: 13 men with high sensitivity to UV light took 160 mg a day of Opextan for 4 weeks, then the back was exposed to graded UVA plus UVB doses. The paper's abstract and Indena's Japanese brochure call it placebo-controlled, while Indena's English page says Opextan "or not". Published only as one of three short studies in a paper by Indena-linked authors in an Italian dermatology journal not indexed in PubMed; only the abstract was available to check. (Togni et al. 2015, Esperienze Dermatologiche)
13 men selected for high sensitivity to UV light; how they were split between Opextan and placebo, and their ages, are not stated in the material available.
The paper's abstract reports that the minimal erythemal dose, the smallest UV dose that reddens the skin, rose 14.5 percent and the tolerated UV exposure time 14.1 percent versus placebo; Indena's brochure instead reports a 16.45 percent rise from baseline (p < 0.01). The figures differ between sources, and individual data and side effect information were not available, so the size of any effect cannot be judged.
Before-and-after study: healthy volunteers took 400 mg a day of Opextan for 4 weeks, and urinary 8-isoprostane, a lipid peroxidation marker, was measured at the start and end. No control group is described in Indena's Japanese brochure or in the abstract of the summary paper by Indena-linked authors, which appeared in an Italian dermatology journal not indexed in PubMed. (Togni et al. 2015, Esperienze Dermatologiche)
19 healthy volunteers (number from Indena's brochure); sex and age are not stated.
The paper's abstract reports a 36.4 percent fall in urinary 8-isoprostane, while Indena's brochure reports 47 percent (p < 0.05), and the brochure's own chart shows that several participants rose. Without a control group, a fall from baseline cannot be separated from chance or regression toward the mean. No side effects are described; the published 12-week trial paper mentions a 28-day human test at 400 mg a day with no adverse events.
Randomized, double-blind, placebo-controlled parallel trial in hospital outpatients in Japan. The extract, called OPDEX in the paper and made by Indena from Coratina olives (about 10 percent polyphenols, 3.2 percent acteoside, 2.9 percent hydroxytyrosol), was given as two 50 mg soft capsules daily after breakfast; placebo was olive oil capsules. Indena cites this trial for Opextan. Three of the four authors worked for Kanebo Cosmetics, Opextan's co-developer, though the paper declares no conflicts. Not PubMed-indexed. (Suzuki et al. 2011, Ningen Dock)
15 outpatients of Mitsui Memorial Hospital treated for high blood pressure (with an ARB, a calcium channel blocker or both) whose fasting glucose was in the borderline range; 9 men and 6 women, mean age 63; 8 took the extract and 7 placebo.
Fasting glucose fell from 116.6 to 105.8 mg/dL within the extract group (p = 0.042) and did not change with placebo (107.3 to 109.3 mg/dL); no between-group test of this change is reported, and the extract group started higher. HbA1c, insulin, HOMA-IR, HOMA-beta, urinary 8-OHdG, blood pressure and blood lipids did not change. No adverse events occurred, and the authors note the sample was small.